Cost-effectiveness analysis of the treatment with enalapril of chronic heart failure in Spain [Análisis coste efectividad del tratamiento con enalapril de la insuficiencia cardíaca crónica en España.]

  1. Antoñanzas Villar, F. 1
  2. Antón Botella, F. 1
  3. Echevarría Echarri, L. 1
  1. 1 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

Revista:
Gaceta Sanitaria

ISSN: 0213-9111

Año de publicación: 1996

Volumen: 10

Número: 54

Páginas: 135-142

Tipo: Artículo

DOI: 10.1016/S0213-9111(96)71886-1 PMID: 8991882 SCOPUS: 2-s2.0-16744362394 GOOGLE SCHOLAR

Otras publicaciones en: Gaceta Sanitaria

Repositorio institucional: lock_openAcceso abierto Editor

Resumen

The aim of this study is to analyse in terms of cost-effectiveness the utilisation of enalapril as part of chronic heart failure therapy in Spain. A computer spread sheet based upon the results of the treatment arm of the SOLVD (Studies on Left Ventricular Dysfunction) study was used, with costs and epidemiologic data referred to Spain. Epidemiologic data are extrapolations from either studies performed in other countries or estimates from hospital and outpatient clinics utilisation, and economic data are taken from Spanish studies. The time horizon of the study was set at four years, and results are referred to year 1993. Widespread use of enalapril increases survival in 1.7 months per individual or in 5-10,000 years for the whole population. It generates net savings for the health system estimated in 1,500 to 3,000 million pesetas, also in four years. Using enalapril as part of the standard therapy for chronic heart failure generates an increase both in saved years of life and quality of life, and is associated with net savings for the health system.